Pharmacotherapy Publishing Inc
View my basket
Atypon Link logo

You have no access to this article

Enhanced Antithrombotic Effect of Warfarin Associated with Low-Dose Alcohol Consumption


Author(s): Dawn E. Havrda | Tien Mai | Jennifer Chonlahan
doi: 10.1592/phco.25.2.303.56955
Prev | Table of contents | Next
 
View PDF article (93 K) View references
Email this link
 What is RSS?
Trouble viewing articles as PDF?
 
  Pharmacotherapy
 
Print ISSN: 0277-0008
Volume: 25 | Issue: 2
Cover date: February 2005
Page(s): 303-307
 
 
  Key Words
 
alcohol, ethanol, ethyl alcohol, anticoagulation, international normalized ratio, INR, warfarin
 
  Abstract

A 58-year-old Caucasian man was receiving long-term anticoagulation with warfarin for the prevention of ischemic stroke; his international normalized ratio (INR) had been stable. His INR increased when he began consistent, low-dose beer consumption for its perceived cardiovascular protection. After he stopped drinking the alcohol, his anticoagulation control improved and returned to previous levels. Information on the effects of alcohol, particularly beer, is limited in nonalcoholic patients who receive warfarin therapy. This case reveals a potential for low-dose beer consumption to elevate INR. We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system. Concurrent administration of aspirin and other drugs that are metabolized through or are inhibitors of the CYP system may have enhanced the interaction that occurred in this patient. Caution should be used whenever warfarin and alcohol in any amount are taken together, especially in patients receiving many drugs, and close monitoring of the INR is warranted.

 
  Author(s) affiliations
 
1. Department of Pharmacy Practice, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, Virginia.
Address reprint requests to Dawn E. Havrda, Pharm.D., BCPS, Bernard J. Dunn School of Pharmacy, Shenandoah University, 1775 North Sector Court, Winchester, VA 22601.
2. Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, Oklahoma.
3. Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, Oklahoma.
 
  This article has been cited by:
1.
 
WARFARIN THERAPY, VITAMIN K AND OTHER DIETARY FACTORS.
Nutrition & Dietetics |  66 |  2 |  123-128
CrossRef
2.
 
Effect of Ethanol on S-Warfarin and Diclofenac Metabolism by Recombinant Human CYP2C9.1.
Akitoshi Tatsumi, Yuki Ikegami, Ryoko Morii, Masatoshi Sugiyama, Muneo Kadobayashi, Seigo Iwakawa.
Biological & Pharmaceutical Bulletin |  32 |  3 |  517-519
CrossRef
3.
 
Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on Warfarin.
NA Limdi, G McGwin, JA Goldstein, TM Beasley, DK Arnett, BK Adler, MF Baird, RT Acton.
Clinical Pharmacology & Therapeutics |  83 |  2 |  312
CrossRef
4.
 
Drug interactions involving ethanol and alcoholic beverages.
Graham R Jang, Robert Z Harris.
Expert Opinion on Drug Metabolism & Toxicology |  3 |  5 |  719-731
CrossRef
5.
 
Risk of Warfarin-Related Bleeding Events and Supratherapeutic International Normalized Ratios Associated with Complementary and Alternative Medicine: A Longitudinal Analysis.
Stephen Shalansky, Larry Lynd, Kathryn Richardson, Andrew Ingaszewski, Charles Kerr.
Pharmacotherapy |  27 |  9 |  1237-1247
View Header/Abstract | View PDF article (391 KB) | PDF Plus (172 KB) 
6.
 
Influence of CYP2C9 genotype on warfarin dose among African–Americans and European–Americans.
Nita A Limdi, JA Goldstein, JA Blaisdell, TM Beasley, CA Rivers, RT Acton.
Personalized Medicine |  4 |  2 |  157
CrossRef
7.
 
Warfarin and its interactions with foods, herbs and other dietary supplements.
Edith A Nutescu, Nancy L Shapiro, Sonia Ibrahim, Patricia West.
Expert Opinion on Drug Safety |  5 |  3 |  433-451
CrossRef
8.
 
Increase in International Normalized Ratio After Smoking Cessation in a Patient Receiving Warfarin.
Mark Evans, , Geoffrey M. Lewis, .
Pharmacotherapy |  25 |  11 |  1656-1659
View Header/Abstract | View References | View PDF article (59 KB)